On September 8, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BriaCell’s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine’s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.
"We are pleased to welcome MSK as a clinical site in BriaCell’s Phase 3 study," stated Dr. William V. Williams, BriaCell’s President & CEO. "MSK is one of the world’s leading cancer centers, and its participation expands patient access to the Bria-IMT regimen as we continue advancing a potential new therapeutic approach for heavily pretreated patients."
"We are pleased that MSK is now enrolling patients in BriaCell’s pivotal Phase 3 study evaluating Bria-IMT for advanced breast cancer in patients with limited therapeutic options. We look forward to collaborating with BriaCell," commented Phaedon Zavras, MD, the MSK Breast Medical Oncologist and Assistant Attending Physician who is serving as principal investigator for the MSK study site.
BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT in combination with an immune check point inhibitor (CPI), compared with physician’s choice of treatment in advanced metastatic breast cancer (the Bria-ABC study).
The study’s primary endpoint is overall survival (OS). An interim analysis is planned after 144 deaths have occurred, comparing OS in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice. BriaCell recently received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase 3 Study in metastatic breast cancer. At ASCO (Free ASCO Whitepaper) 2026, BriaCell also announced positive Phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.
For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT please visit ClinicalTrials.gov NCT06072612.
Memorial Sloan Kettering Cancer Center (MSK) has institutional financial interests related to BriaCell.
(Press release, BriaCell Therapeutics, SEP 8, 2026, View Source [SID1234670652])